Author/Authors :
Hirohata، نويسنده , , Atsushi and Yamamoto، نويسنده , , Keizo and Miyoshi، نويسنده , , Toru and Hatanaka، نويسنده , , Kunihiko and Hirohata، نويسنده , , Satoshi and Yamawaki، نويسنده , , Hitoshi and Komatsubara، نويسنده , , Issei and Murakami، نويسنده , , Masaaki and Hirose، نويسنده , , Eiki and Sato، نويسنده , , Shinji and Ohkawa، نويسنده , , Keisuke and Ishizawa، نويسنده , , Makoto and Yamaji، نويسنده , , Hirosuke and Kawamura، نويسنده , , Hiroshi and Kusachi، نويسنده , , Shozo and Murakami، نويسنده , , Takashi and Hina، نويسنده , , Kazuyoshi and Ohe، نويسنده , , Tohru، نويسنده ,
Abstract :
Objectives
m of this study was to evaluate the impact of olmesartan on progression of coronary atherosclerosis.
ound
intravascular ultrasound (IVUS) trial results suggest slowing of coronary atheroma progression with some medicines but have not shown convincing evidence of regression with angiotension-II receptor blocking agents.
s
pective, randomized, multicenter trial—OLIVUS (Impact of OLmesartan on progression of coronary atherosclerosis: evaluation by IntraVascular UltraSound)—was performed in 247 stable angina pectoris patients with native coronary artery disease. When these patients underwent percutaneous coronary intervention for culprit lesions, IVUS was performed in their nonculprit vessels (without angiographically documented coronary stenosis [<50%]). Patients were randomly assigned to receive 10 to 40 mg of olmesartan or control and treated with a combination of beta-blockers, calcium channel blockers, diuretics, nitrates, glycemic control agents, and/or statins per physicianʹs guidance. Serial IVUS examinations (baseline and 14-month follow-up) were performed to assess coronary atheroma volume. Volumetric IVUS analyses included lumen, plaque, vessel volume, percent atheroma volume (PAV), percent change in total atheroma volume (TAV) and PAV.
s
t characteristics and blood pressure control were identical between the 2 groups. However, follow-up IVUS showed significantly decreased TAV and percent change in PAV in the olmesartan group (5.4% vs. 0.6 % for TAV and 3.1% vs. −0.7% for percent change in PAV, control vs. olmesartan, p < 0.05 for all).
sions
observations suggest a positive role in a potentially lower rate of coronary atheroma progression through the administration of olmesartan, an angiotension-II receptor blocking agent, for patients with stable angina pectoris.
Keywords :
Arteriosclerosis , atherosclerosis , Prevention , ultrasonics , Angiotensin
